| A1AT | Alpha-1 antitrypsin |
| ApoA-1 | Apolipoprotein A-1 |
| CD2AP | CD2 Associated Protein |
| CFP | Complement factor P (properdin) |
| CKD-EPI | Chronic Kidney Disease Epidemiology Collaboration formula |
| ECM | Extracellular matrix |
| ESI | Electrospray ionization |
| eGFR | Estimated glomerular filtration rate |
| FASP | Filter-aided sample preparation |
| FSGS | Focal segmental glomerulosclerosis |
| GBM | Glomerular basement membrane |
| HDL | High-density lipoprotein |
| HPLC | High-performance liquid chromatography |
| LC-MS | Liquid chromatography—mass spectrometry |
| LC-MS/MS | Liquid chromatography with tandem mass spectrometry |
| LC/MRM-MS | Liquid chromatography/Multiple reaction monitoring—mass spectrometry |
| LDL | Low density lipoproteins |
| MALDI-TOF MS | Matrix-Assisted Laser Desorption—Ionisation-Time of Flight Mass Spectrometry |
| MCD | Minimal change disease |
| MRM | Multiple reaction monitoring |
| MS | Mass spectrometry |
| NAT | Natural synthetic proteotypic peptides |
| NS | Nephrotic syndrome |
| PASEF | Parallel Accumulation—Serial Fragmentation method |
| PEDF | Pigment epithelium-derived factor |
| SIS | Stable isotope labelled peptide standards |
| TIF | Tubulointerstitial fibrosis |